Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shunxi Holding Group
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Shunxi Holding Group has licensed Cartherics’ autologous CAR-T product CTH-004 targeting TAG-72 for multiple solid tumors including ovarian cancer in Greater China; CTH-004 has shown promising activity in animal models and is planned for evaluation in clinical trials in collaboration with Peter MacCallum Cancer Centre, with Shunxi to lead pre-clinical and clinical development in China.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyCAR-T cell therapyStem cell therapy
- Industry
- Biotech
02
Partnerships
Cartherics (license to develop, manufacture and commercialize CTH-004 for multiple solid tumors including ovarian cancer in Greater China)
Beyond the preview
Go deeper on Shunxi Holding Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shunxi Holding Group.